touchRESPIRATORY coverage of ERS 2024:
The unmet need for effective treatments for childhood interstitial lung diseases (ILDs) is significant, with no drugs currently approved for this vulnerable population—unlike in adult patients. Addressing this gap, the InPedILD trial demonstrated an acceptable safety profile for nintedanib compared to placebo in children and adolescents aged 6 to 17 years with fibrosing ILDs. Building on these promising findings, the InPedILD-ON open-label extension study aims to further evaluate the long-term safety and tolerability of nintedanib in pediatric patients.
In this interview, Prof. Matthias Griese shares key insights from the interim analysis of InPedILD-ON presented at ERS 2024, highlighting its potential to shape future treatment options for fibrosing ILDs in children and adolescents.
Full abstract from ERS 2024: Nintedanib in children and adolescents with fibrosing ILDs: interim analysis of InPedILD-ON
Questions:
- What are the current unmet needs in the treatment options for childhood fibrosing interstitial lung diseases (ILDs)?
- Could you share insights from the interim analysis of the InPedILD-ON study presented at ERS 2024?
- What are the next steps?
- What other research findings in childhood ILDs were highlighted at ERS 2024?
Disclosures: Prof. Matthias Griese has been a consultant and advisory board participant for Böhringer Ingelheim.
Interviewer/Editor: Nicola Cartridge
Cite: Griese M. Interim analysis from InPedILD-ON shows tolerability of nintedanib in children and adolescents with fibrosing ILDs. touchRESPIRATORY. November 20, 2024.
This content has been developed independently by Touch Medical Media for touchRESPIRATORY. It is not affiliated with the European Respiratory Society (ERS). Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. No endorsement of unapproved products or unapproved uses is either made or implied by mention of these products or uses by Touch Medical Media or any sponsor. Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.
